Baltoji biotechnologija - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | - | - | - | 26,697 | 51,726 | 60,093 | 192,632 |
| Profit before tax | 0 | 0 | 0 | 0 | 1,163 | 213 | 5,715 | 3,941 |
| Net profit | 0 | 0 | 0 | 0 | 1,104 | 199 | 5,363 | 3,603 |
| Equity | -14 | -14 | -14 | -14 | 1,091 | 1,290 | 6,654 | 14,587 |
| Liabilities | - | - | - | - | 6,168 | 5,281 | 7,670 | 41,745 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 1,358 | 1,735 | 30,686 |
| Current assets | 0 | 0 | 0 | 0 | 7,259 | 5,213 | 12,589 | 25,646 |
| Total assets | 0 | 0 | 0 | 0 | 7,259 | 6,571 | 14,324 | 56,332 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 8,559 | 8,636 | 7,929 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | - | - | - | +93.8% | +16.2% | +220.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | - | - | - | 15.2% | 3.0% | 37.4% | 6.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | 101.2% | 15.4% | 80.6% | 24.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | 4.1% | 0.4% | 8.9% | 1.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 4.4% | 0.4% | 9.5% | 2.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 5.7 | 4.1 | 1.2 | 2.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Baltoji biotechnologija - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-03 | 2026-05-31 | 160.96 |
| 2026-03-03 | 2026-04-30 | 160.96 |
| 2026-02-03 | 2026-03-02 | 80.48 |
| 2026-01-01 | 2026-01-31 | 152.85 |
| 2025-12-02 | 2025-12-31 | 80.40 |
| 2025-09-02 | 2025-12-01 | 7.95 |
| 2025-07-01 | 2025-08-31 | 7.95 |
| 2024-11-04 | 2024-11-11 | 64.50 |
| 2024-10-01 | 2024-10-31 | 193.50 |
| 2024-09-03 | 2024-09-30 | 129.00 |
| 2024-08-01 | 2024-09-02 | 64.50 |
| 2024-07-02 | 2024-07-31 | 193.50 |
| 2024-06-03 | 2024-07-01 | 129.00 |
| 2024-05-02 | 2024-06-02 | 64.50 |
| 2024-04-03 | 2024-04-30 | 129.00 |
| 2024-03-01 | 2024-04-02 | 64.50 |
| 2024-02-01 | 2024-02-29 | 240.39 |
| 2024-01-03 | 2024-01-31 | 175.89 |
| 2023-12-01 | 2024-01-02 | 117.26 |
| 2023-11-03 | 2023-11-30 | 58.63 |
| 2023-10-03 | 2023-10-31 | 172.49 |
| 2023-09-01 | 2023-10-02 | 113.86 |
| 2023-08-09 | 2023-08-31 | 55.23 |
| 2023-08-01 | 2023-08-08 | 58.63 |
| 2023-07-03 | 2023-07-31 | 175.89 |
| 2023-06-01 | 2023-07-02 | 117.26 |
| 2023-05-16 | 2023-05-31 | 58.63 |
| 2023-05-04 | 2023-05-15 | 237.92 |
| 2023-05-02 | 2023-05-03 | 179.29 |
| 2023-04-03 | 2023-04-30 | 179.29 |
| 2023-03-01 | 2023-04-02 | 120.66 |
| 2023-02-01 | 2023-02-28 | 62.03 |
| 2023-01-26 | 2023-01-31 | 3.40 |
| 2023-01-03 | 2023-01-25 | 98.50 |
| 2022-12-01 | 2023-01-02 | 47.55 |
| 2022-11-03 | 2022-11-30 | 50.95 |
| 2022-10-03 | 2022-10-31 | 50.95 |
| 2022-09-23 | 2022-09-30 | 133.40 |
| 2022-09-01 | 2022-09-22 | 152.85 |
| 2022-08-02 | 2022-08-31 | 101.90 |
| 2022-07-01 | 2022-08-01 | 50.95 |
| 2022-06-01 | 2022-06-30 | 54.34 |
| 2022-05-27 | 2022-05-31 | 3.39 |
Baltoji biotechnologija - VMI tax arrears
As of 2026-10-07, the amount of overdue STI tax debt of the company Baltoji biotechnologija is: 2 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-25 | 2026-10-07 | 2.1 |
| 2026-09-04 | 2026-09-24 | 0.66 |
| 2026-09-01 | 2026-09-03 | 1368.63 |
| 2026-08-28 | 2026-08-31 | 1366.47 |
| 2026-08-26 | 2026-08-27 | 940.47 |
| 2026-08-05 | 2026-08-25 | 934.97 |
| 2026-08-02 | 2026-08-04 | 934.22 |
| 2026-07-01 | 2026-08-01 | 0.22 |
| 2026-01-29 | 2026-02-03 | 0.69 |
| 2026-01-27 | 2026-01-28 | 531.77 |
| 2026-01-24 | 2026-01-26 | 528.78 |
| 2026-01-22 | 2026-01-23 | 494.8 |
| 2025-09-28 | 2025-09-29 | 629.31 |
| 2025-09-01 | 2025-09-03 | 855.43 |
| 2025-08-28 | 2025-08-31 | 854.11 |
| 2025-08-27 | 2025-08-27 | 0.11 |
| 2025-08-06 | 2025-08-26 | 0.1 |
| 2025-08-05 | 2025-08-05 | 27.1 |
| 2025-08-01 | 2025-08-04 | 27.06 |
| 2025-07-28 | 2025-07-31 | 27.0 |
| 2025-07-01 | 2025-07-27 | 1.27 |
| 2025-06-28 | 2025-06-30 | 414.63 |
| 2025-06-25 | 2025-06-27 | 0.63 |
| 2025-06-24 | 2025-06-24 | 330.6 |
| 2025-06-19 | 2025-06-23 | 329.97 |
| 2025-04-28 | 2025-04-28 | 575.49 |
| 2025-04-02 | 2025-04-02 | 0.37 |
| 2025-03-31 | 2025-04-01 | 91.58 |
| 2025-03-28 | 2025-03-30 | 91.63 |
| 2025-02-28 | 2025-02-28 | 781.42 |
| 2025-01-01 | 2025-01-24 | 0.3 |
| 2024-12-30 | 2024-12-30 | 379.2 |
| 2024-12-24 | 2024-12-29 | 1.2 |
| 2024-12-03 | 2024-12-23 | 0.2 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Baltoji biotechnologija, MB (code 304072719) is a Lithuanian small partnership operating in other non-specialised retail sale. In 2025, the company generated revenue of €192.6K, up 220.6% year on year and 272.4% compared with 2023. Net profit was €3.6K, which means profitability remained positive but the margin narrowed to 1.9% from 8.9% in 2024. The business therefore showed strong top-line expansion, while earnings moderated from the prior year. Over the three-year period, revenue rose from €51.7K in 2023 to €60.1K in 2024 and then increased sharply in 2025, whereas net profit moved from €199 in 2023 to €5.4K in 2024 and €3.6K in 2025. At year-end 2025, total assets stood at €56.3K, equity at €14.6K and liabilities at €41.7K. Long-term assets were €30.7K and short-term assets €25.6K. Key ratios for 2025 show return on equity of 24.7%, return on assets of 6.4%, debt-to-equity of 2.86 and asset turnover of 3.42x, indicating relatively efficient asset use with a higher leverage profile.